These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

234 related articles for article (PubMed ID: 17045087)

  • 41. Immunotherapy for renal cell cancer in the era of targeted therapy.
    Coppin C
    Expert Rev Anticancer Ther; 2008 Jun; 8(6):907-19. PubMed ID: 18533800
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Interleukin-21: updated review of Phase I and II clinical trials in metastatic renal cell carcinoma, metastatic melanoma and relapsed/refractory indolent non-Hodgkin's lymphoma.
    Hashmi MH; Van Veldhuizen PJ
    Expert Opin Biol Ther; 2010 May; 10(5):807-17. PubMed ID: 20384523
    [TBL] [Abstract][Full Text] [Related]  

  • 43. [Interleukin-2 and interferon in metastatic kidney cancer. Experience of the French Immunotherapy Group].
    Negrier S; Douillard JY; Gomez F; Lasset C; Chevreau C; Escudier B;
    Prog Urol; 2002 Apr; 12(2):213-8. PubMed ID: 12108334
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Retinoids and metastatic renal cell carcinoma.
    Paule B; Brion N
    Ann Med Interne (Paris); 1997; 148(7):496-501. PubMed ID: 9538388
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Increased disease activity in a patient with sarcoidosis after high dose interleukin 2 treatment for metastatic renal cancer.
    Logan TF; Bensadoun ES
    Thorax; 2005 Jul; 60(7):610-1. PubMed ID: 15994271
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Contemporary trends in high-dose interleukin-2 use for metastatic renal cell carcinoma in the United States.
    Allard CB; Gelpi-Hammerschmidt F; Harshman LC; Choueiri TK; Faiena I; Modi P; Chung BI; Tinay I; Singer EA; Chang SL
    Urol Oncol; 2015 Nov; 33(11):496.e11-6. PubMed ID: 26210683
    [TBL] [Abstract][Full Text] [Related]  

  • 47. New therapeutic developments in renal cell cancer.
    Prenen H; Gil T; Awada A
    Crit Rev Oncol Hematol; 2009 Jan; 69(1):56-63. PubMed ID: 18752971
    [TBL] [Abstract][Full Text] [Related]  

  • 48. High-dose interleukin-2 therapy for metastatic renal cell carcinoma and metastatic melanoma: still the standard.
    Dutcher JP
    Oncology (Williston Park); 2011 Apr; 25(5):427-8. PubMed ID: 21710841
    [No Abstract]   [Full Text] [Related]  

  • 49. Regression of metastatic clear cell kidney cancer with interleukin-2 treatment following nivolumab (anti-PD-1) treatment.
    Brayer J; Fishman M
    J Immunother; 2014 Apr; 37(3):187-91. PubMed ID: 24598453
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Ipsilateral right testicular metastasis from renal cell carcinoma in a responder patient to interleukine-2 treatment.
    Camerini A; Tartarelli G; Martini L; Donati S; Puccinelli P; Amoroso D
    Int J Urol; 2007 Mar; 14(3):259-60. PubMed ID: 17430270
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Update on the medical treatment of metastatic renal cell carcinoma.
    Ravaud A; Wallerand H; Culine S; Bernhard JC; Fergelot P; Bensalah K; Patard JJ
    Eur Urol; 2008 Aug; 54(2):315-25. PubMed ID: 18485581
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Prognostic implications of polymorphisms and interleukin-2 therapy for renal cell carcinoma.
    Gardner TA; Logan T
    J Urol; 2009 Aug; 182(2):425-6. PubMed ID: 19524946
    [No Abstract]   [Full Text] [Related]  

  • 53. Recurrence of pemphigus vulgaris associated with interleukin 2 therapy.
    Prussick R; Plott RT; Stanley JR
    Arch Dermatol; 1994 Jul; 130(7):890-3. PubMed ID: 7794299
    [TBL] [Abstract][Full Text] [Related]  

  • 54. [Two cases of renal cell carcinoma with ascites after interleukin-2 therapy].
    Kobori G; Maegawa M; Ushida H; Maekawa S; Inoue K; Kaneko Y; Ohmori K; Nishimura K
    Hinyokika Kiyo; 2002 Jul; 48(7):455-7. PubMed ID: 12229188
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Complete response in a cutaneous facial metastatic nodule from renal cell carcinoma after hypofractionated radiotherapy.
    Gay HA; Cavalieri R; Allison RR; Finley J; Quan WD
    Dermatol Online J; 2007 Oct; 13(4):6. PubMed ID: 18319003
    [TBL] [Abstract][Full Text] [Related]  

  • 56. [Perioperative immune modulation in renal cell carcinoma--review of the current situation].
    Böhm M; Klatte T; Allhoff EP
    Aktuelle Urol; 2003 Sep; 34(5):319-27. PubMed ID: 14566659
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Interleukin-2 for the treatment of melanoma.
    Tarhini AA; Agarwala SS
    Curr Opin Investig Drugs; 2005 Dec; 6(12):1234-9. PubMed ID: 16370388
    [TBL] [Abstract][Full Text] [Related]  

  • 58. New drug therapies for advanced renal cell carcinoma.
    Gore ME; Harrison ML; Montes A
    Expert Rev Anticancer Ther; 2007 Jan; 7(1):57-71. PubMed ID: 17187520
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Renal cell carcinoma: new developments in molecular biology and potential for targeted therapies.
    Costa LJ; Drabkin HA
    Oncologist; 2007 Dec; 12(12):1404-15. PubMed ID: 18165617
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Developing a rational tumor vaccine therapy for renal cell carcinoma: immune yin and yang.
    Ernstoff MS; Crocenzi TS; Seigne JD; Crosby NA; Cole BF; Fisher JL; Uhlenhake JC; Mellinger D; Foster C; Farnham CJ; Mackay K; Szczepiorkowski ZM; Webber SM; Schned AR; Harris RD; Barth RJ; Heaney JA; Noelle RJ
    Clin Cancer Res; 2007 Jan; 13(2 Pt 2):733s-740s. PubMed ID: 17255302
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 12.